Breaking News Instant updates and real-time market news.

IONS

Ionis Pharmaceuticals

$36.38

0.72 (2.02%)

, ALNY

Alnylam

$70.30

1.73 (2.52%)

17:26
10/05/16
10/05
17:26
10/05/16
17:26

Ionis Pharmaceuticals down 5.2% after Alnylam drug development halt

IONS

Ionis Pharmaceuticals

$36.38

0.72 (2.02%)

ALNY

Alnylam

$70.30

1.73 (2.52%)

  • 07

    Oct

  • 14

    Oct

  • 06

    Nov

IONS Ionis Pharmaceuticals
$36.38

0.72 (2.02%)

09/26/16
PIPR
09/26/16
NO CHANGE
Target $46
PIPR
Overweight
Ionis nusinersen program advancing faster than expected, says Piper Jaffray
After Biogen (BIIB) and Ionis (IONS) announced that Biogen has completed the rolling submission of a New Drug Application to the U.S. FDA for the approval of nusinersen, an investigational treatment for spinal muscular atrophy, Piper Jaffray analyst Joshua Schimmer said that the nusinersen program is advancing faster than many have expected. Nusinersen may launch before AveXis (AVXS) starts its next Phase 3 trial, added Schimmer, who believes nusinersen will emerge as a multi-billion dollar product. The analyst keeps an Overweight rating and $46 price target on Ionis shares.
09/28/16
JEFF
09/28/16
NO CHANGE
Target $50
JEFF
Buy
Jefferies parent survey shows interest in AveXis pivotal trial
Jefferies analyst Biren Amin conducted a survey of parents of spinal muscular atrophy patients amid investor questions surrounding AveXis' (AVXS) ability to enroll a pivotal trial with AVXS-101 given the open access program with nusinersen, the investigational drug being developed by Ionis Pharmaceuticals (IONS) and Biogen (BIIB). Parents value the option of nusinersen treatment but are also willing to enroll in clinical trials of AVXS-101, Amin tells investors in a research note, citing his survey of seven parents. A single arm trial of AVXS-101 was the most preferred clinical trial design for the upcoming Phase 3 of AVXS-101, he added. The analyst believes his parent responses suggest excitement over nusinersen but also a willingness to enroll into the AVXS-101 trials, especially if it is a single-arm trial. Parents were also attracted to AVXS-101 intravenous delivery, which could be a "meaningful advantage," Amin contends. The analyst keeps a Buy rating on AveXis with a $50 price target. The stock closed yesterday up 88c to $41.00. Amin caused a rally in AveXis shares on September 19 when writing about finding a video online of a spinal muscular atrophy baby walking that he believed to be a patient in the company's trial of AVXS-101.
09/28/16
JANY
09/28/16
INITIATION
Target $47
JANY
Buy
Ionis Pharmaceuticals initiated with a Buy at Janney Capital
Janney Capital analyst Roy Buchanan initiated Ionis Pharmaceuticals with a Buy and a $47 fair value estimate. Buchanan believes the late stage pipeline, including wholly-owned volanesorsen, and the base technology can add meaningful value to Ionis. 1H 2017 is particularly rich with 3 phase 3 readouts, with potential for another early, interim look at SMA.
10/04/16
RBCM
10/04/16
NO CHANGE
Target $375
RBCM
Outperform
Biogen could rise $20 or more per share on SMA success, says RBC Capital
RBC Capital analyst Michael Yee expects the first presentation of data from Biogen's (BIIB) Phase III ENDEAR trial studying nusinersen, an investigational treatment for spinal muscular atrophy, or SMA, this week, potentially during the late breaker session at the WMS Congress on October 8. Biogen and partner Ionis Pharmaceuticals (IONS) already announced in August that the study in Type I infants hit the interim analysis and stopped early for positive data. The much larger opportunity in older children has data expected to read out in Spring 2017, noted Yee, who thinks Biogen can have upside from $10 to over $20 per share based on its SMA opportunity. Yee keeps an Outperform rating and $375 price target on Biogen shares.
ALNY Alnylam
$70.30

1.73 (2.52%)

08/22/16
WEDB
08/22/16
NO CHANGE
WEDB
Intellia Therapeutics data positive, says Wedbush
Wedbush analyst David Nierengarten says that additional data on Intella's (NTLA) TTR program in mice was "meaningful" and indicates that the program compares favorably with competing products. The analyst says that competing programs, including those of Alnylam (ALNY) and Ionis (IONS) have shown "only a transient benefit." He reiterates a $38 price target and Outperform rating on Intella.
09/09/16
LEER
09/09/16
NO CHANGE
LEER
Leerink updates therapeutics best ideas for 2016
In a note to investors this morning, Leerink has updated its best ideas for 2016 from the firm's five therapeutics analysts. The list includes Alexion (ALXN), Dermira (DERM), Intra-Cellular (ITCI), Sanofi (SNY), Allergan (AGN), Alnylam (ALNY), Innate Pharma (IPHYF), The Medicines Co. (MDCO), and Ophthotech (OPHT).
09/15/16
FBRC
09/15/16
INITIATION
Target $82
FBRC
Underperform
FBR calls Alexion overvalued, starts shares at Underperform
FBR Capital analyst Christopher James initiated coverage of Alexion Pharmaceuticals (ALXN) with an Underperform rating and $82 price target. The biotech focused on patients with ultra-rare disorders closed yesterday up $2.63 to $129.42. Alexion shares are overpriced as the company is facing a competitive near-term landscape, particularly from Alnylam's (ALNY) ALN-CC5, James tells investors in a research note. Further, near-term expansion into additional indications will be challenging given the recent failed study with eculizumab in refractory generalized myasthenia gravis, the analyst contends. He also sees possible pricing pressures from biosimilars, including an Amgen (AMGN) biosimilar product in development. James this morning also initiated Achillion Pharmaceuticals (ACHN) and Arena Pharmaceuticals (ARNA) with Outperform ratings.
09/28/16
JANY
09/28/16
INITIATION
Target $74
JANY
Neutral
Alnylam initiated with a Neutral at Janney Capital
Janney Capital analyst Roy Buchanan initiated Alnylam with a Neutral and a $74 fair value estimate. The analyst is not confident about the outcome for the pivotal study for patisiran in transthyretin familial amyloid neuropathy, expected in about 12 months, and give patisiran a 50% chance of success.

TODAY'S FREE FLY STORIES

AAL

American Airlines

$45.31

-0.69 (-1.50%)

11:25
09/19/17
09/19
11:25
09/19/17
11:25
Options
American Airlines call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

HQY

HealthEquity

$45.77

0.65 (1.44%)

11:25
09/19/17
09/19
11:25
09/19/17
11:25
Conference/Events
HealthEquity participates in a conference call with Chardan »

Conference call with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 25

    Sep

NHI

National Health Investors

$79.82

-0.175 (-0.22%)

11:25
09/19/17
09/19
11:25
09/19/17
11:25
Conference/Events
National Health Investors to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

OPXA

Opexa Therapeutics

$1.09

0.07 (6.86%)

11:25
09/19/17
09/19
11:25
09/19/17
11:25
Conference/Events
Opexa Therapeutics to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

JKS

JinkoSolar

$27.78

0.14 (0.51%)

, JASO

JA Solar

$8.14

0.25 (3.17%)

11:21
09/19/17
09/19
11:21
09/19/17
11:21
Periodicals
EU eases trade restrictions on Chinese solar panels, People's Daily reports »

China has welcomed the…

JKS

JinkoSolar

$27.78

0.14 (0.51%)

JASO

JA Solar

$8.14

0.25 (3.17%)

CSIQ

Canadian Solar

$16.80

-0.47 (-2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUVA

NuVasive

$57.80

-0.68 (-1.16%)

, EFII

Electronics for Imaging

$41.56

-0.03 (-0.07%)

11:21
09/19/17
09/19
11:21
09/19/17
11:21
Hot Stocks
NuVasive slides as GlassHouse Research sees 'profusion of accounting red flags' »

GlassHouse Research noted…

NUVA

NuVasive

$57.80

-0.68 (-1.16%)

EFII

Electronics for Imaging

$41.56

-0.03 (-0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 20

    Sep

  • 21

    Sep

$NSD

NASDAQ Market Internals

11:17
09/19/17
09/19
11:17
09/19/17
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIR

AAR Corp.

$36.87

0.32 (0.88%)

11:16
09/19/17
09/19
11:16
09/19/17
11:16
Hot Stocks
AAR Corp. to acquire two MRO facilities from Premier Aviation »

AAR announced that it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

$NYE

NYSE Market Internals

11:16
09/19/17
09/19
11:16
09/19/17
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
09/19/17
09/19
11:15
09/19/17
11:15
General news
Breaking General news story  »

4-Week Bill Auction to be…

BBY

Best Buy

$52.43

-4.92 (-8.58%)

11:13
09/19/17
09/19
11:13
09/19/17
11:13
Technical Analysis
Technical View: Best Buy falls to session lows following outlook »

The shares have been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

SIEGY

Siemens

$69.98

0.26 (0.37%)

11:11
09/19/17
09/19
11:11
09/19/17
11:11
Hot Stocks
Siemens, PAS announce partnership to provide monitoring for control systems »

Siemens and PAS Global…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$58.51

0.395 (0.68%)

11:10
09/19/17
09/19
11:10
09/19/17
11:10
Options
Repeat of bullish option activity in UAL »

Repeat of bullish option…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

VIAB

Viacom

$27.32

-0.35 (-1.26%)

, DISCA

Discovery

$21.32

-0.62 (-2.83%)

11:08
09/19/17
09/19
11:08
09/19/17
11:08
Hot Stocks
Cowen sees more trouble ahead for traditional TV names »

Research firm Cowen cut…

VIAB

Viacom

$27.32

-0.35 (-1.26%)

DISCA

Discovery

$21.32

-0.62 (-2.83%)

FOXA

21st Century Fox

$26.50

-0.55 (-2.03%)

DIS

Disney

$98.43

0.325 (0.33%)

CBS

CBS

$57.71

-0.01 (-0.02%)

GOOGL

Alphabet Class A

$929.75

-5.54 (-0.59%)

GOOG

Alphabet

$915.00

-5.29 (-0.57%)

FB

Facebook

$170.01

-1.63 (-0.95%)

NFLX

Netflix

$184.62

2.27 (1.24%)

AMZN

Amazon.com

$974.19

-12.6 (-1.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 28

    Sep

  • 02

    Oct

  • 16

    Oct

  • 29

    Nov

XON

Intrexon

$19.19

-0.28 (-1.44%)

11:07
09/19/17
09/19
11:07
09/19/17
11:07
Hot Stocks
Intrexon's Oxitec plans to build centralized mosquito egg production unit »

Oxitec, a wholly owned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRCM

Care.com

$14.45

-0.14 (-0.96%)

11:04
09/19/17
09/19
11:04
09/19/17
11:04
Hot Stocks
Care.com names George Bell to board as lead independent director »

Care.com yesterday…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTB

M&T Bank

$152.67

1 (0.66%)

11:03
09/19/17
09/19
11:03
09/19/17
11:03
Hot Stocks
M&T Bank enters community-focused strategic partnership with NY Jets »

The New York Jets and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNC

Centene

$88.33

-6.25 (-6.61%)

11:02
09/19/17
09/19
11:02
09/19/17
11:02
Hot Stocks
Coordinated Care awarded Commendable Accreditation status from NCQA »

Coordinated Care, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 24

    Oct

USB

U.S. Bancorp

$52.64

0.255 (0.49%)

11:01
09/19/17
09/19
11:01
09/19/17
11:01
Hot Stocks
U.S. Bancorp boosts quarterly dividend by 7% to 30c »

U.S. Bancorp said its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 17

    Jan

NUVA

NuVasive

$57.80

-0.68 (-1.16%)

11:01
09/19/17
09/19
11:01
09/19/17
11:01
Periodicals
NuVasive mentioned cautiously in short report from GlassHouse Research 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RGC

Regal Entertainment

$16.08

-0.365 (-2.22%)

11:00
09/19/17
09/19
11:00
09/19/17
11:00
Conference/Events
Regal Entertainment management to meet with MKM Partners »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 28

    Sep

  • 02

    Oct

T

AT&T

$37.94

0.515 (1.38%)

11:00
09/19/17
09/19
11:00
09/19/17
11:00
Options
AT&T option volume double normal as implied volatility term structure inverts »

AT&T option volume…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

KR

Kroger

$21.32

-0.12 (-0.56%)

10:59
09/19/17
09/19
10:59
09/19/17
10:59
Hot Stocks
Kroger outlook revised to Negative from Stable by Fitch »

Fitch affirmed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Oct

  • 30

    Nov

TSLA

Tesla

$385.00

5.19 (1.37%)

10:58
09/19/17
09/19
10:58
09/19/17
10:58
Conference/Events
Tesla management to meet with MKM Partners »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 19

    Sep

  • 02

    Oct

WK

Workiva

$19.75

-0.15 (-0.75%)

10:55
09/19/17
09/19
10:55
09/19/17
10:55
Conference/Events
Workiva to host analyst day »

Analyst Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 19

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.